{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T02:20:00Z","timestamp":1704421200030},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[1989,7,1]],"date-time":"1989-07-01T00:00:00Z","timestamp":615254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1989,7,1]],"date-time":"1989-07-01T00:00:00Z","timestamp":615254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1989,7]]},"DOI":"10.1007\/bf00170865","type":"journal-article","created":{"date-parts":[[2004,8,15]],"date-time":"2004-08-15T19:14:44Z","timestamp":1092597284000},"page":"235-238","source":"Crossref","is-referenced-by-count":6,"title":["Phase II study of esorubicin (4\u2032-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study"],"prefix":"10.1007","volume":"7","author":[{"given":"William P.","family":"McGuire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Yordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackson","family":"Beecham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"12","key":"BF00170865_CR1","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/jm00234a016","volume":"19","author":"F Arcamone","year":"1976","unstructured":"Arcamone F, Penco S, Redaelli S, Hanessian S: Synthesis and antitumor activity of 4\u2032-deoxydaunorubicin and 4\u2032-deoxyadriamycin. J Med Chem 19(12): 1424\u20131425, 1976","journal-title":"J Med Chem"},{"key":"BF00170865_CR2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.1984.2.4.282","volume":"2","author":"SE Salmon","year":"1984","unstructured":"Salmon SE, Young L, Soehulen B, Liu R: Antitumor activity of esorubicin in human tumor clonogenic assay with comparison to doxorubicin. J Clin Oncol 2:282\u2013286, 1984","journal-title":"J Clin Oncol"},{"key":"BF00170865_CR3","first-page":"4682","volume":"40","author":"FC Giuliani","year":"1980","unstructured":"Giuliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin resistant colon tumor xenograft in the nude mouse. Cancer Res 40:4682\u20134687, 1980","journal-title":"Cancer Res"},{"key":"BF00170865_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0277-5379(83)90140-2","volume":"19","author":"AM Casazza","year":"1983","unstructured":"Casazza AM, Savi G, Pratesi G, DiMarco A: Antitumor activity in mice of 4\u2032-deoxydoxorubicin in comparison to doxorubicin. Eur J Cancer Clin Oncol 19:411\u2013418, 1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF00170865_CR5","first-page":"223","volume":"3","author":"F Villani","year":"1985","unstructured":"Villani F, Comazzi R, Genitoni V: Preliminary evaluation of myocardial toxicity of 4\u2032-deoxydoxorubicin: Experimental and clinical results. Drugs Explt Clin Res 3:223\u2013231, 1985","journal-title":"Drugs Explt Clin Res"},{"issue":"4","key":"BF00170865_CR6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00177414","volume":"1","author":"M Rozencweig","year":"1983","unstructured":"Rozencweig M, Crespeigne N, Kenis Y: Phase I trial with 4\u2032-deoxydoxorubicin (esorubicin). Invest New Drugs 1(4): 309\u2013313, 1983","journal-title":"Invest New Drugs"},{"issue":"9","key":"BF00170865_CR7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.1984.2.9.1034","volume":"2","author":"HS Garewal","year":"1984","unstructured":"Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R: Phase I trial of esorubicin (4\u2032-deoxydoxorubicin). J Clin Oncol 2(9): 1034\u20131039, 1984","journal-title":"J Clin Oncol"},{"issue":"7","key":"BF00170865_CR8","first-page":"765","volume":"71","author":"GY Locker","year":"1987","unstructured":"Locker GY, Hoeltgen T, Kilton L, Krauss S, McNamara M, Blough R, Johnson C: Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: An Illinois Cancer Council trial. Cancer Treat Rep 71(7):765\u2013766, 1987","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"BF00170865_CR9","first-page":"427","volume":"71","author":"RW Carlson","year":"1987","unstructured":"Carlson RW, Billingham ME, Kohler M, Johnson FD, Doroshow JH, Torti FM: Esorubicin in refractory metastatic carcinoma of the breast: A Northern California Oncology Group study. Cancer Treat Rep 71(4):427\u2013428, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00170865_CR10","unstructured":"Zagonel V, Tirelli U, Vaccher E, Sorio R, Saracchini S, Monfardini S: Activity of 4\u2032-deoxydoxorubicin (esorubicin) in patients with plasma cell tumors: A phase II study. Proc Fifth EORTC Symposium New Drugs, 1986"},{"issue":"7","key":"BF00170865_CR11","first-page":"783","volume":"71","author":"MG Kris","year":"1987","unstructured":"Kris MG, Gralla RJ, Burke MT, Fiore JJ, Kelsen DP, Marks LD, Heelan RT: Phase II trial of esorubicin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 71(7):783\u2013784, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00170865_CR12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00175303","volume":"5","author":"S Frustaci","year":"1987","unstructured":"Frustaci S, Gasparini G, Veronesi A, Tirelli U, Pacciarini MA, Crivellari D, Zagonel V, Monfardini S: Phase II study of esorubicin (4\u2032-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. Invest New Drugs 5:307\u2013309, 1987","journal-title":"Invest New Drugs"},{"issue":"2","key":"BF00170865_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00194602","volume":"4","author":"T Braich","year":"1986","unstructured":"Braich T, Ahmann FR, Garewal HS, Robertone A, Salmon SE: Phase II trial of 4\u2032-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer. Invest New Drugs 4(2): 193\u2013196, 1986","journal-title":"Invest New Drugs"},{"issue":"7","key":"BF00170865_CR14","first-page":"767","volume":"71","author":"RW Carlson","year":"1987","unstructured":"Carlson RW, Williams RD, Billingham ME, Kohler M, Torti F: Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: A study of the Northern California Oncology Group. Cancer Treat 71(7):767\u2013768, 1987","journal-title":"Cancer Treat"},{"issue":"3","key":"BF00170865_CR15","first-page":"325","volume":"71","author":"S Frustaci","year":"1987","unstructured":"Frustaci S, Gasparini G, Galligioni E, Tirelli U, Di Pietro N, Crivellari D, Lo Re G, Monfardini S: Phase II trial of esorubicin in patients with advanced melanoma. Cancer Treat Rep 71(3):325\u2013326, 1987","journal-title":"Cancer Treat Rep"},{"key":"BF00170865_CR16","first-page":"83","volume":"6","author":"S Ringenberg","year":"1987","unstructured":"Ringenberg S, Propert K, Perry M, Weiss RB, Modeas C, Richards F, Graziano S, Hirsh V, Green M: Clinical cardiotoxicity of esorubicin: A prospective study with serial gaited heart scans and report of selected cases. Proc Am Soc Clin Oncol 6:83, 1987","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"4","key":"BF00170865_CR17","first-page":"345","volume":"3","author":"RS Freedman","year":"1980","unstructured":"Freedman RS, Herson J, Wharton JT, Rutledge FN: Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin Trials 3(4):345\u2013350, 1980","journal-title":"Cancer Clin Trials"},{"issue":"10","key":"BF00170865_CR18","first-page":"1435","volume":"62","author":"HJ Wallace","year":"1978","unstructured":"Wallace HJ, Hreshchyshyn MM, Wilbanks GD, Boronow RC, Fowler jr. WC, Blessing JA: Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 62(10):1435\u20131441, 1978","journal-title":"Cancer Treat Rep"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00170865\/fulltext.html","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00170865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00170865\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00170865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00170865.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:42:22Z","timestamp":1678560142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00170865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,7]]},"references-count":18,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[1989,7]]}},"alternative-id":["BF00170865"],"URL":"https:\/\/doi.org\/10.1007\/bf00170865","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,7]]}}}